Published in J Hyg (Lond) on September 01, 1969
The relevance of the anti-human globulin (Coombs) test and the complement-fixation test in the diagnosis of brucellosis. J Hyg (Lond) (1970) 1.07
Symptomatology of chronic brucellosis. Br J Ind Med (1973) 0.98
Brucellosis in veterinary surgeons. Br Med J (1970) 0.75
Technique of complementfixation test applicable to the diagnosis of virus diseases. Mon Bull Minist Health Public Health Lab Serv (1962) 17.29
The laboratory diagnosis of chronic brucellosis. Lancet (1966) 3.01
The antiglobulin (Coombs) test in brucellosis. Lancet (1951) 2.25
Brucellosis--an island epidemiological study. Br Med J (1961) 1.73
Chronic brucellosis. Q J Med (1953) 1.72
Brucellosis control and eradication. Public Health (1963) 1.15
The anti-globulin sensitization test as applied to brucella infection; a preliminary report. Med J Aust (1953) 1.05
Brucella abortus agglutinins in the sera of pregnant women and blood donors. Br J Prev Soc Med (1963) 1.03
Human Brucella antiglobulin titres in the Pretoria area. S Afr J Lab Clin Med (1956) 0.97
Milk-borne diseases. An epidemiological review. Lancet (1966) 0.93
Incomplete antibodies in brucellosis; an indirect antiglobulin (Coombs) one-tube screen test. S Afr Med J (1958) 0.85
Epidemiology of human brucellosis in the United Kingdom. Br J Prev Soc Med (1963) 0.84
Echocardiography in chronic heart failure in the community. Q J Med (1993) 7.64
Primary non-compliance with prescribed medication in primary care. BMJ (1993) 6.80
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Association of road-traffic accidents with benzodiazepine use. Lancet (1998) 4.01
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Techniques and interpretations in the serological diagnosis of brucellosis in man. J Med Microbiol (1968) 3.14
The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol (1977) 3.13
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ (1996) 2.51
Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ (1997) 2.39
Introducing a drug formulary to general practice--effects on practice prescribing costs. J R Coll Gen Pract (1987) 2.24
Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol (1989) 2.06
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut (1997) 1.98
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
A double-blind placebo-controlled trial of theophylline in general practice. Br J Clin Pract (1991) 1.93
Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur J Clin Pharmacol (1989) 1.88
Is maintenance digoxin necessary in patients with sinus rhythm? Lancet (1979) 1.86
Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med (1994) 1.86
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
An epidemiological study of digoxin prescribing in general practice. J R Coll Gen Pract (1986) 1.66
Simultaneous measurement of cardiac output and its distribution with microspheres in the rat. Cardiovasc Res (1976) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther (1976) 1.62
Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax (1993) 1.51
beta-Adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol (1978) 1.50
Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol (1989) 1.48
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Adverse reactions and interactions with beta-adrenoceptor blocking drugs. Med Toxicol (1987) 1.44
Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline. Br J Clin Pharmacol (1983) 1.44
Digoxin compliance in patients from general practice. Br J Clin Pharmacol (1978) 1.38
Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol (1993) 1.37
Plasma concentrations and the time-course of beta blockade due to propranolol. Clin Pharmacol Ther (1975) 1.36
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis (1985) 1.31
Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol (1988) 1.31
Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med (1989) 1.31
Investigation of diurnal changes in the disposition of theophylline. Br J Clin Pharmacol (1983) 1.29
Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects. Br J Clin Pharmacol (1989) 1.29
Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther (1983) 1.22
Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM (1995) 1.21
Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade. Eur J Clin Pharmacol (1989) 1.21
Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax (1992) 1.21
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis (1989) 1.20
Plasma theophylline concentrations following the oral administration of microcrystalline theophylline and a new sustained-release theophylline preparation to normal subjects. Eur J Clin Pharmacol (1980) 1.20
Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine. Br J Clin Pharmacol (1983) 1.19
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax (1995) 1.19
Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood. Br J Clin Pharmacol (1988) 1.19
A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol (1991) 1.17
Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway. Br J Clin Pharmacol (1988) 1.17
Adrenoceptor blocking drugs: clinical pharmacology and therapeutic use. Drugs (1979) 1.17
Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease. Br J Clin Pharmacol (1984) 1.15
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax (1995) 1.12
Vagal activity is increased during intravenous isoprenaline infusion in man. Br J Clin Pharmacol (1984) 1.11
Comparative trial of propranolol and practolol in hyperthyroidism. Br J Clin Pharmacol (1975) 1.11
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
General practitioners' use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions. J R Soc Med (1992) 1.10
A comparison of verapamil and digoxin in the treatment of atrial fibrillation. Eur Heart J (1987) 1.10
Propranolol in the treatment of thyrotoxicosis: a review. Postgrad Med J (1976) 1.07
Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol (1980) 1.07
Central effects of single oral doses of propranolol in man. Br J Clin Pharmacol (1984) 1.07
Digoxin withdrawal after cardiac failure in patients with sinus rhythm. J Cardiovasc Pharmacol (1983) 1.07
The relevance of the anti-human globulin (Coombs) test and the complement-fixation test in the diagnosis of brucellosis. J Hyg (Lond) (1970) 1.07
Do patients take digoxin? Br Heart J (1978) 1.06
Suppression of ventricular ectopic depolarizations by tocainide. Circulation (1977) 1.06
An assessment of physiological finger tremor as an indicator of beta-adrenoceptor function. Br J Clin Pharmacol (1983) 1.05
Lupus-like syndrome induced by procainamide. Br Med J (1967) 1.05
Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. Eur J Clin Pharmacol (1990) 1.03
Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.03
Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. Br J Clin Pharmacol (1992) 1.03
The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med (1993) 1.03
Does the frequency of daily dosage influence compliance with digoxin therapy? Br J Clin Pharmacol (1981) 1.02
Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis (1990) 1.02
Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. Eur J Clin Pharmacol (1991) 1.02
Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant? Drugs (1983) 1.01
Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood. Br J Clin Pharmacol (1990) 1.00
Variations of plasma digoxin concentrations in the equilibrium state after multiple dosing. Br J Clin Pharmacol (1978) 1.00
Symptomatology of chronic brucellosis. Br J Ind Med (1973) 0.98
Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol (1994) 0.97
Investigation of putative cardiac beta 3-adrenoceptors in man. Q J Med (1993) 0.97
Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol (1978) 0.96
Reflex vagal withdrawal and the hemodynamic response to intravenous isoproterenol in the presence of beta-antagonists. Clin Pharmacol Ther (1986) 0.96
Influence of sex-steroid hormones on the regulation of lymphocyte beta 2-adrenoceptors during the menstrual cycle. Br J Clin Pharmacol (1994) 0.95
Clinical pharmacologists for the future in the United Kingdom. Clin Pharmacol Ther (1986) 0.95
Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation. Br J Clin Pharmacol (1982) 0.94
Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability. Br J Clin Pharmacol (1988) 0.92
Effects of thyroid dysfunction on propranolol kinetics. Clin Pharmacol Ther (1980) 0.92
Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J (1988) 0.92
Digitalis: its place in modern therapy. Drugs (1980) 0.92
Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance? Br J Clin Pharmacol (1992) 0.92
The utilisation and economic evaluation of antibiotics prescribed in primary care. J Antimicrob Chemother (1995) 0.91
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol (1989) 0.91
Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway. Br J Clin Pharmacol (1990) 0.91
Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG). Eur J Clin Pharmacol (1986) 0.91